BCRX
NASDAQ · Biotechnology
Biocryst Pharmaceuticals Inc
$7.69
+0.06 (+0.79%)
Financial Highlights (FY 2026)
Revenue
920.39M
Net Income
277.62M
Gross Margin
97.8%
Profit Margin
30.2%
Rev Growth
+47.8%
D/E Ratio
2.09
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 97.8% | 97.8% | 44.3% | 44.3% |
| Operating Margin | 37.0% | 33.3% | -20.4% | -18.7% |
| Profit Margin | 30.2% | 28.7% | -17.3% | -18.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 920.39M | 622.60M | 328.14M | 317.43M |
| Gross Profit | 900.33M | 609.03M | 145.32M | 140.58M |
| Operating Income | 340.55M | 207.33M | -67,015,157 | -59,369,563 |
| Net Income | 277.62M | 169.01M | -56,674,354 | -58,578,347 |
| Gross Margin | 97.8% | 97.8% | 44.3% | 44.3% |
| Operating Margin | 37.0% | 33.3% | -20.4% | -18.7% |
| Profit Margin | 30.2% | 28.7% | -17.3% | -18.5% |
| Rev Growth | +47.8% | +47.8% | +7.1% | +23.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 640.85M | 640.85M | 92.91M | 118.94M |
| Total Equity | 307.19M | 307.19M | 596.71M | 574.48M |
| D/E Ratio | 2.09 | 2.09 | 0.16 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 341.98M | 219.77M | -75,730,538 | -85,752,478 |
| Free Cash Flow | — | — | -52,199,092 | -47,303,254 |